PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PACIRA BIOSCIENCES, INC. (PCRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $22.56 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $21.14, a 17.58% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $25.65, a 19.72% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $31.95, a 17.93% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $38.93, a 37.45% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $25.14, a 9.60% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $27.81, a 27.26% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $38.23, a 36.27% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $59.99, a 0.46% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.56 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $21.14 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $25.14 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $25.30 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $25.45 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $25.65 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $27.81 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $30.87 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $31.46 10-Q · filed 2024-07-30 | |||
| 2024-03-31 | $31.95 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $38.23 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $39.13 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $39.15 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $38.93 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $59.99 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $60.16 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $60.22 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $62.24 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $60.27 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $61.33 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $61.42 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $65.49 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $47.50 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $47.27 10-Q · filed 2020-10-30 | |||
| 2020-06-30 | $46.72 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |